Kiniksa Pharmaceuticals EBITDA vs. Net Income
| KNSA Stock | USD 21.17 0.68 3.11% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -22.9 M | Current Value -24 M | Quarterly Volatility 58.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.62 | 0.7909 |
|
|
For Kiniksa Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiniksa Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiniksa Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiniksa Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiniksa Pharmaceuticals over time as well as its relative position and ranking within its peers.
Kiniksa |
Kiniksa Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kiniksa Pharmaceuticals Net Income vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kiniksa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiniksa Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Kiniksa Pharmaceuticals is rated second overall in ebitda category among its peers. It also is rated second overall in net income category among its peers . At present, Kiniksa Pharmaceuticals' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiniksa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kiniksa Net Income vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Kiniksa Pharmaceuticals |
| = | (22.86 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Kiniksa Pharmaceuticals |
| = | 14.08 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Kiniksa Net Income Comparison
Kiniksa Pharmaceuticals is currently under evaluation in net income category among its peers.
Kiniksa Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kiniksa Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kiniksa Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Kiniksa Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Kiniksa Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 6 K | 6.3 K | |
| Net Interest Income | 1.1 M | 1.6 M | |
| Interest Income | 1.1 M | 1.6 M | |
| Operating Income | -25.2 M | -26.5 M | |
| Net Loss | -6.7 M | -7 M | |
| Income Before Tax | -16.7 M | -17.5 M | |
| Total Other Income Expense Net | 8.5 M | 9 M | |
| Net Income Applicable To Common Shares | 210.9 M | 221.4 M | |
| Net Income | 14.1 M | 14.8 M | |
| Income Tax Expense | -30.7 M | -32.3 M | |
| Non Operating Income Net Other | 1.1 M | 2.1 M | |
| Change To Netincome | -144.3 M | -137.1 M | |
| Net Income Per Share | 0.20 | 0.21 | |
| Income Quality | 0.94 | 0.84 | |
| Net Loss | (0.85) | (0.80) |
Kiniksa Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kiniksa Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kiniksa Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kiniksa Pharmaceuticals' important profitability drivers and their relationship over time.
Use Kiniksa Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiniksa Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiniksa Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Kiniksa Pharmaceuticals Pair Trading
Kiniksa Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Kiniksa Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiniksa Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiniksa Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiniksa Pharmaceuticals to buy it.
The correlation of Kiniksa Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiniksa Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiniksa Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiniksa Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kiniksa Pharmaceuticals position
In addition to having Kiniksa Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 260 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
To fully project Kiniksa Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kiniksa Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kiniksa Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.